Ocular FIP treatment moves toward clearer dosing guidance

CURRENT FULL VERSION: Ocular FIP is getting a sharper clinical focus as veterinary educators and researchers revisit how antiviral treatment should be adapted for cats with eye involvement. VetGirl’s recent podcast coverage lands amid a broader shift in FIP care: what was once largely discussed through case reports, informal networks, and unregulated drug access is now being framed by published treatment data, updated feline medicine guidance, and a more defined, if still imperfect, U.S. regulatory pathway for compounded GS-441524. (fda.gov)

That shift has been years in the making. Earlier GS-441524 field studies excluded cats with ocular or neurologic signs because of concerns about drug penetration into the eye and central nervous system. Over time, however, clinical experience and retrospective data pushed the field toward treating these cats more aggressively rather than viewing them as poor candidates. A 2024 retrospective study of 307 cats treated with legally sourced compounded remdesivir and GS-441524 described how the evidence base evolved beyond those early exclusions, while later guidance documents began distinguishing ocular FIP from uncomplicated effusive or non-effusive disease in practical dosing recommendations. VetGirl’s newer educational coverage also reflects how far the conversation has moved beyond “can we treat this?” to “how should we diagnose, dose, and monitor it in real practice?” (pmc.ncbi.nlm.nih.gov)

One of the clearest research signals came in a 2025 observational case series focused specifically on cats with ocular involvement. The authors evaluated 20 cats with FIP-associated ocular disease treated with remdesivir, GS-441524, or both, noting that most began on injectable remdesivir, while a smaller subset received oral GS-441524 alone. Most were treated in the 15-20 mg/kg range, and the paper notes that higher doses up to 20 mg/kg are commonly recommended when ocular or neurologic involvement is present. The authors also cited prior work showing aqueous humor concentrations of GS-441524 reached 22%-33% of plasma levels, helping explain why clinicians have leaned toward dose escalation in these cases. VetGirl’s review of the paper adds practical context for generalists by emphasizing what ocular FIP can look like at presentation: anterior chamber changes such as keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, and fibrinous exudate, along with posterior segment findings including tapetal or non-tapetal retinal lesions, retinal hemorrhage or vascular tortuosity, retinal detachment, and perivascular cuffing. The podcast also notes that ocular involvement is seen far more often in non-effusive than effusive FIP, and in some cats uveitis may be the dominant presenting sign rather than a later complication. (pmc.ncbi.nlm.nih.gov)

Current feline-specific guidance reflects that same logic. The Feline Veterinary Medical Association’s 2025 FIP update guide recommends oral GS-441524 at 20 mg/kg every 24 hours, or split every 12 hours, for ocular FIP, compared with 15 mg/kg for cases without ocular or neurologic signs. The guide also notes that divided dosing may improve plasma concentrations and that oral GS-441524 remains the preferred first-line therapy among nucleoside analogues, with protease inhibitors positioned more as adjuncts for refractory, relapsed, or severe cases. That practical emphasis on tailoring protocols is also showing up in continuing education around dosing and duration, where speakers are increasingly asking whether higher induction dosing and more objective treatment-stop criteria could shorten therapy safely in some cats while still accounting for sanctuary sites such as the eye and central nervous system. (catvets.com)

The dosing-duration question is becoming more important as FIP care moves from rescue-driven improvisation toward protocol refinement. In a separate 2025 VetGirl podcast reviewing a 46-case paper on high-dose induction therapy and treatment termination criteria, the discussion highlighted a familiar clinical tension: many cats improve within the first week of antiviral treatment, but early improvement does not necessarily mean viral clearance. The podcast pointed to growing interest in using acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, along with the albumin:globulin ratio and their trends over time, as more objective markers to help guide treatment duration and stopping decisions. For ocular and neurologic disease in particular, that matters because longer treatment courses have traditionally been favored to address tissues that are harder for antivirals to penetrate, even when cost is a major concern for clients.

The regulatory backdrop matters, too. On May 10, 2024, the FDA said it did not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat with FIP under the conditions in Guidance for Industry #256. At the same time, the agency stressed that compounded products from bulk drug substances are still unapproved drugs, not approved or fully legal in the conventional sense. That distinction is important for veterinary teams because it affects how they discuss access, consent, sourcing, and expectations with pet parents. (fda.gov)

Industry reaction since then has centered on access and standardization. AAHA reported in 2024 that veterinarian-prescribed compounded treatment for FIP had become available in the U.S. and Canada, marking a major change from the period when many pet parents relied on gray-market channels. More recently, Wedgewood Pharmacy announced in June 2025 that it had added a compounded oral GS-441524 formulation to its FIP treatment portfolio, underscoring how mainstream veterinary pharmacy infrastructure is beginning to form around these cases. (aaha.org)

Broader FIP education is evolving alongside treatment access. VetGirl’s recent “real practice” diagnostic update framed FIP as a disease that still often requires a presumptive diagnosis built from signalment, risk factors, clinicopathologic patterns, imaging, and body cavity fluid findings rather than a single definitive test. That podcast revisited familiar epidemiology — including the role of feline enteric coronavirus exposure in young cats from multicat environments and the fact that only a minority go on to develop FIP after viral mutation — while also emphasizing that clinicians should not over-anchor on age alone. The same practical thread runs through dvm360’s VetBlast discussion on “demystifying” FIP, which highlighted how frustrating diagnosis can remain in everyday practice even as treatment outcomes improve.

Why it matters: For practicing veterinarians, ocular FIP now sits at the intersection of ophthalmology, infectious disease, pharmacy, and client communication. The key takeaway isn’t simply that treatment exists. It’s that ocular involvement may warrant different dosing, closer follow-up, and a lower threshold for reassessment if inflammation, glaucoma, retinal changes, or neurologic crossover signs persist. It also means practices need workflows for discussing compounded antiviral status clearly, documenting treatment rationale, and setting realistic expectations around duration, cost, relapse risk, and the limits of available comparative data. And because many FIP cases are still diagnosed presumptively, teams need a practical, repeatable approach to combining ocular findings with systemic clues and serial monitoring rather than waiting for perfect certainty. (pmc.ncbi.nlm.nih.gov)

What to watch: The next developments will likely come from larger real-world cohorts, more standardized outcome reporting for ocular signs, and additional guidance on when to escalate dose, split dosing, extend treatment, or pivot to alternative antivirals in refractory cases. Expect continued interest, too, in biomarker-guided duration decisions and in how compounded formulations perform across ocular and neurologic presentations in routine practice. (pmc.ncbi.nlm.nih.gov)